세포치료제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)

Cell Therapy Market - Scope of Report

TMR's report on the global cell therapy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global cell therapy market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cell therapy market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the cell therapy market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cell therapy market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cell therapy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cell therapy market.

The report delves into the competitive landscape of the global cell therapy market. Key players operating in the global cell therapy market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cell therapy market profiled in this report.

Key Questions Answered in Global cell therapy Market Report:

• What is the sales/revenue generated by cell therapy across all regions during the forecast period?
• What are the opportunities in the global cell therapy market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Cell Therapy Market - Research Objectives and Research Approach

The comprehensive report on the global cell therapy market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cell therapy market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cell therapy market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Cell Therapy Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Cell Therapy Market Analysis and Forecasts, 2020-2034

5. Key Insights

• 5.1. Porter's Five Forces Analysis
• 5.2. PEST Analysis
• 5.3. Key Industry Events - Product Approvals
• 5.4. Key Industry Events - Partnerships and Collaborations

6. Global Cell Therapy Market Analysis and Forecasts, By Type

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Type, 2020-2034
  • 6.3.1. T-cell Therapy
    • 6.3.1.1. Chimeric Antigen Receptor (CAR) T-cells
    • 6.3.1.2. T-cell Receptors
    • 6.3.1.3. Tumor-Infiltrating Lymphocytes
  • 6.3.2. Stem Cell Therapy
  • 6.3.3. Natural Killer Cells
  • 6.3.4. Dendritic Cells
  • 6.3.5. Other Cell Therapies
• 6.4. Market Attractiveness By Type

7. Global Cell Therapy Market Analysis and Forecasts, By Origin

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Origin, 2020-2034
  • 7.3.1. Autologous Therapies
  • 7.3.2. Allogenic Therapies
• 7.4. Market Attractiveness By Origin

8. Global Cell Therapy Market Analysis and Forecasts, By Therapeutic Area

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By Therapeutic Area, 2020-2034
  • 8.3.1. Oncological Disorders
  • 8.3.2. Autoimmune Disorders
  • 8.3.3. Neurological Disorders
  • 8.3.4. Others
• 8.4. Market Attractiveness By Therapeutic Area

9. Global Cell Therapy Market Analysis and Forecasts, By Region

• 9.1. Key Findings
• 9.2. Market Value Forecast By Region
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness By Country/Region

10. North America Cell Therapy Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast By Type, 2020-2034
  • 10.2.1. T-cell Therapy
    • 10.2.1.1. Chimeric Antigen Receptor (CAR) T-cells
    • 10.2.1.2. T-cell Receptors
    • 10.2.1.3. Tumor-Infiltrating Lymphocytes
  • 10.2.2. Stem Cell Therapy
  • 10.2.3. Natural Killer Cells
  • 10.2.4. Dendritic Cells
  • 10.2.5. Other Cell Therapies
• 10.3. Market Value Forecast By Origin, 2020-2034
  • 10.3.1. Autologous Therapies
  • 10.3.2. Allogenic Therapies
• 10.4. Market Value Forecast By Therapeutic Area, 2020-2034
  • 10.4.1. Oncological Disorders
  • 10.4.2. Autoimmune Disorders
  • 10.4.3. Neurological Disorders
  • 10.4.4. Others
• 10.5. Market Value Forecast By Country, 2020-2034
  • 10.5.1. U.S.
  • 10.5.2. Canada
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Type
  • 10.6.2. By Origin
  • 10.6.3. By Therapeutic Area
  • 10.6.4. By Country

11. Europe Cell Therapy Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast By Type, 2020-2034
  • 11.2.1. T-cell Therapy
    • 11.2.1.1. Chimeric Antigen Receptor (CAR) T-cells
    • 11.2.1.2. T-cell Receptors
    • 11.2.1.3. Tumor-Infiltrating Lymphocytes
  • 11.2.2. Stem Cell Therapy
  • 11.2.3. Natural Killer Cells
  • 11.2.4. Dendritic Cells
  • 11.2.5. Other Cell Therapies
• 11.3. Market Value Forecast By Origin, 2020-2034
  • 11.3.1. Autologous Therapies
  • 11.3.2. Allogenic Therapies
• 11.4. Market Value Forecast By Therapeutic Area, 2020-2034
  • 11.4.1. Oncological Disorders
  • 11.4.2. Autoimmune Disorders
  • 11.4.3. Neurological Disorders
  • 11.4.4. Others
• 11.5. Market Value Forecast By Country/Sub-region, 2020-2034
  • 11.5.1. Germany
  • 11.5.2. U.K.
  • 11.5.3. France
  • 11.5.4. Italy
  • 11.5.5. Spain
  • 11.5.6. Rest of Europe
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Type
  • 11.6.2. By Origin
  • 11.6.3. By Therapeutic Area
  • 11.6.4. By Country/Sub-region

12. Asia Pacific Cell Therapy Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Type, 2020-2034
  • 12.2.1. T-cell Therapy
    • 12.2.1.1. Chimeric Antigen Receptor (CAR) T-cells
    • 12.2.1.2. T-cell Receptors
    • 12.2.1.3. Tumor-Infiltrating Lymphocytes
  • 12.2.2. Stem Cell Therapy
  • 12.2.3. Natural Killer Cells
  • 12.2.4. Dendritic Cells
  • 12.2.5. Other Cell Therapies
• 12.3. Market Value Forecast By Origin, 2020-2034
  • 12.3.1. Autologous Therapies
  • 12.3.2. Allogenic Therapies
• 12.4. Market Value Forecast By Therapeutic Area, 2020-2034
  • 12.4.1. Oncological Disorders
  • 12.4.2. Autoimmune Disorders
  • 12.4.3. Neurological Disorders
  • 12.4.4. Others
• 12.5. Market Value Forecast By Country/Sub-region, 2020-2034
  • 12.5.1. China
  • 12.5.2. India
  • 12.5.3. Japan
  • 12.5.4. Australia & New Zealand
  • 12.5.5. Rest of Asia Pacific
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Type
  • 12.6.2. By Origin
  • 12.6.3. By Therapeutic Area
  • 12.6.4. By Country/Sub-region

13. Latin America Cell Therapy Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Type, 2020-2034
  • 13.2.1. T-cell Therapy
    • 13.2.1.1. Chimeric Antigen Receptor (CAR) T-cells
    • 13.2.1.2. T-cell Receptors
    • 13.2.1.3. Tumor-Infiltrating Lymphocytes
  • 13.2.2. Stem Cell Therapy
  • 13.2.3. Natural Killer Cells
  • 13.2.4. Dendritic Cells
  • 13.2.5. Other Cell Therapies
• 13.3. Market Value Forecast By Origin, 2020-2034
  • 13.3.1. Autologous Therapies
  • 13.3.2. Allogenic Therapies
• 13.4. Market Value Forecast By Therapeutic Area, 2020-2034
  • 13.4.1. Oncological Disorders
  • 13.4.2. Autoimmune Disorders
  • 13.4.3. Neurological Disorders
  • 13.4.4. Others
• 13.5. Market Value Forecast By Country/Sub-region, 2020-2034
  • 13.5.1. Brazil
  • 13.5.2. Mexico
  • 13.5.3. Rest of Latin America
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Type
  • 13.6.2. By Origin
  • 13.6.3. By Therapeutic Area
  • 13.6.4. By Country/Sub-region

14. Middle East & Africa Cell Therapy Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Type, 2020-2034
  • 14.2.1. T-cell Therapy
    • 14.2.1.1. Chimeric Antigen Receptor (CAR) T-cells
    • 14.2.1.2. T-cell Receptors
    • 14.2.1.3. Tumor-Infiltrating Lymphocytes
  • 14.2.2. Stem Cell Therapy
  • 14.2.3. Natural Killer Cells
  • 14.2.4. Dendritic Cells
  • 14.2.5. Other Cell Therapies
• 14.3. Market Value Forecast By Origin, 2020-2034
  • 14.3.1. Autologous Therapies
  • 14.3.2. Allogenic Therapies
• 14.4. Market Value Forecast By Therapeutic Area, 2020-2034
  • 14.4.1. Oncological Disorders
  • 14.4.2. Autoimmune Disorders
  • 14.4.3. Neurological Disorders
  • 14.4.4. Others
• 14.5. Market Value Forecast By Country/Sub-region, 2020-2034
  • 14.5.1. GCC
  • 14.5.2. South Africa
  • 14.5.3. Rest of Middle East & Africa
• 14.6. Market Attractiveness Analysis
  • 14.6.1. By Type
  • 14.6.2. By Origin
  • 14.6.3. By Therapeutic Area
  • 14.6.4. By Country/Sub-region

15. Competition Landscape

• 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 15.2. Market Share Analysis By Company (2023)
• 15.3. Company Profiles
  • 15.3.1. Novartis AG
    • 15.3.1.1. Company Overview
    • 15.3.1.2. Financial Overview
    • 15.3.1.3. Product Portfolio
    • 15.3.1.4. Business Strategies
    • 15.3.1.5. Recent Developments
  • 15.3.2. Bristol-Myers Squibb Company
    • 15.3.2.1. Company Overview
    • 15.3.2.2. Financial Overview
    • 15.3.2.3. Product Portfolio
    • 15.3.2.4. Business Strategies
    • 15.3.2.5. Recent Developments
  • 15.3.3. IOVANCE Biotherapeutics, Inc.
    • 15.3.3.1. Company Overview
    • 15.3.3.2. Financial Overview
    • 15.3.3.3. Product Portfolio
    • 15.3.3.4. Business Strategies
    • 15.3.3.5. Recent Developments
  • 15.3.4. Janssen Biotech, Inc.
    • 15.3.4.1. Company Overview
    • 15.3.4.2. Financial Overview
    • 15.3.4.3. Product Portfolio
    • 15.3.4.4. Business Strategies
    • 15.3.4.5. Recent Developments
  • 15.3.5. CellTrans, Inc.
    • 15.3.5.1. Company Overview
    • 15.3.5.2. Financial Overview
    • 15.3.5.3. Product Portfolio
    • 15.3.5.4. Business Strategies
    • 15.3.5.5. Recent Developments
  • 15.3.6. Gamida Cell Inc.
    • 15.3.6.1. Company Overview
    • 15.3.6.2. Financial Overview
    • 15.3.6.3. Product Portfolio
    • 15.3.6.4. Business Strategies
    • 15.3.6.5. Recent Developments
  • 15.3.7. Dendreon Pharmaceuticals LLC
    • 15.3.7.1. Company Overview
    • 15.3.7.2. Financial Overview
    • 15.3.7.3. Product Portfolio
    • 15.3.7.4. Business Strategies
    • 15.3.7.5. Recent Developments
  • 15.3.8. Kite Pharma, Inc.
    • 15.3.8.1. Company Overview
    • 15.3.8.2. Financial Overview
    • 15.3.8.3. Product Portfolio
    • 15.3.8.4. Business Strategies
    • 15.3.8.5. Recent Developments
  • 15.3.9. Adaptimmune
    • 15.3.9.1. Company Overview
    • 15.3.9.2. Financial Overview
    • 15.3.9.3. Product Portfolio
    • 15.3.9.4. Business Strategies
    • 15.3.9.5. Recent Developments
  • 15.3.10. Takeda Pharmaceutical Company Limited
    • 15.3.10.1. Company Overview
    • 15.3.10.2. Financial Overview
    • 15.3.10.3. Product Portfolio
    • 15.3.10.4. Business Strategies
    • 15.3.10.5. Recent Developments